Diabetes therapeutic - Baxter International/Teva Pharmaceutical Industries

Drug Profile

Diabetes therapeutic - Baxter International/Teva Pharmaceutical Industries

Latest Information Update: 15 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International; Teva Pharmaceutical Industries
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 15 Jun 2007 Discontinued - Phase-I for Diabetes mellitus in Europe (Parenteral)
  • 15 Jun 2007 Discontinued - Phase-II for Diabetes mellitus in USA (Parenteral)
  • 28 Nov 2005 Phase-I clinical trials in Diabetes mellitus in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top